Polymer-based delivery of RNA-based therapeutics in ovarian cancer

Methods in Molecular Biology

Volumn 1049, Issue , 2013, Pages 443-465

  Weirauch, Ulrike ^a   Gutsch, Daniela ^b   Höbel, Sabrina ^a   Aigner, Achim ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Gene knockdown; miRNA; miRNA replacement therapy; Nanoparticles; PEI; Polyethylenimine; RNAi; siRNA

Indexed keywords

MESSENGER RNA; MICRORNA; POLYETHYLENEIMINE; SMALL INTERFERING RNA; NANOPARTICLE; POLYMER;

AGAR GEL ELECTROPHORESIS; ARTICLE; AUTORADIOGRAPHY; COMPLEX FORMATION; DEGRADATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; IN VITRO GENE TRANSFER; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA TRANSLATION; SUBSTITUTION THERAPY; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; OVARIAN NEOPLASMS; PATHOLOGY;

DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NANOPARTICLES; OVARIAN NEOPLASMS; POLYMERS; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84881606178     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-547-7_34     Document Type: Article

References (38)

1. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431:343-349
2. Siolas D, Lerner C, Burchard J et al (2005) Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23:227-231
3. de Fougerolles A, Vornlocher HP, Maraganore J et al (2007) Interfering with disease: A progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443-453
4. Aigner A (2007) Applications of RNA interference: Current state and prospects for siRNAbased strategies in vivo. Appl Microbiol Biotechnol 76:9-21
5. Rettig GR, Behlke MA (2011) Progress toward in vivo use of siRNAs-II. Mol Ther 20(3):483-512
6. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297
7. Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38:724-733
8. Aigner A (2011) MicroRNAs (miRNAs) in cancer invasion and metastasis: Therapeutic approaches based on metastasis-related miRNAs. J Mol Med 89:445-457
9. Ibrahim AF, Weirauch U, Thomas M et al (2011) MicroRNA replacement therapy for miR-145 and miR-33a is effi cacious in a model of colon carcinoma. Cancer Res 71(15):5214-5224
10. Grimm D, Streetz KL, Jopling CL et al (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541
11. Merdan T, Kopecek J, Kissel T (2002) Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 54:715-758
12. Aigner A (2008) Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des 14:3603-3619
13. Tang MX, Szoka FC (1997) The infl uence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther 4:823-832
14. Eliyahu H, Barenholz Y, Domb AJ (2005) Polymers for DNA delivery. Molecules 10:34-64
15. Liu F, Huang L (2002) Development of nonviral vectors for systemic gene delivery. J Control Release 78:259-266
16. Basarkar A, Singh J (2007) Nanoparticulate systems for polynucleotide delivery. Int J Nanomedicine 2:353-360
17. Boussif O, Lezoualc'h F, Zanta MA et al (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA 92:7297-7301
18. Lungwitz U, Breunig M, Blunk T et al (2005) Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60:247-266
19. Behr JP (1997) The proton sponge: A trick to enter cells the viruses did not exploit. Chimia 51:34-36
20. Godbey WT, Wu KK, Mikos AG (1999) Size matters: Molecular weight affects the effi ciency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 45:268-275
21. Breunig M, Lungwitz U, Liebl R et al (2007) Breaking up the correlation between effi cacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci USA 104:14454-14459
22. Werth S, Urban-Klein B, Dai L et al (2006) A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection effi -ciency of DNA and siRNA in fresh or lyophilized complexes. J Control Release 112:257-270
23. Urban-Klein B, Werth S, Abuharbeid S et al (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461-466
24. Grzelinski M, Urban-Klein B, Martens T et al (2006) RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine- complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17:751-766
25. Zou SM, Erbacher P, Remy JS et al (2000) Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J Gene Med 2:128-134
26. Boussif O, Zanta MA, Behr JP (1996) Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther 3:1074-1080
27. Hobel S, Prinz R, Malek A et al (2008) Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. Eur J Pharm Biopharm 70(1):29-41
28. Hobel S, Koburger I, John M et al (2010) Polyethylenimine/small interfering RNAmediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 12:287-300
29. Kaestner P, Aigner A, Bastians H (2011) Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo. Cancer Lett 304:128-136
30. Hendruschk S, Wiedemuth R, Aigner A et al (2011) RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol 13:1074-1089
31. Gunther M, Lipka J, Malek A et al (2011) Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 77(3):438-449
32. Ripka S, Neesse A, Riedel J et al (2010) CUX1: Target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 59(8):1101-1110
33. Schulze D, Plohmann P, Hobel S et al (2011) Anti-tumor effects of fi broblast growth factorbinding protein (FGF-BP) knockdown in colon carcinoma. Mol Cancer 10:144
34. Harris JM, Martin NE, Modi M (2001) Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551
35. Malek A, Czubayko F, Aigner A (2008) PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNAinduced gene targeting effi cacy. J Drug Target 16:124-139
36. Malek A, Merkel O, Fink L et al (2009) In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 236:97-108
37. Chen C, Ridzon DA, Broomer AJ et al (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33:e179
38. Malek A, Bakhidze E, Noske A et al (2008) HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123:348-356